Quick Answer
Relay Therapeutics, Inc. reported Cash and Equivalents of $84.02 million for fiscal year 2025.
Relay Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $84.02M | -32.4% |
| 2024 | $124.29M | -13.5% |
| 2023 | $143.74M | -5.3% |
| 2022 | $151.79M | -45.8% |
| 2021 | $280.12M | -37.4% |
| 2020 | $447.65M | +967.0% |
| 2019 | $41.95M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $91.56M | -39.9% | -19.6% |
| June 30, 2025 | $113.94M | -15.0% | +21.8% |
| March 31, 2025 | $93.54M | -38.8% | -24.7% |
| December 31, 2024 | $124.29M | -13.5% | -18.4% |
| September 30, 2024 | $152.36M | +0.7% | +13.6% |
| June 30, 2024 | $134.12M | -8.1% | -12.3% |
| March 31, 2024 | $152.87M | -5.2% | +6.4% |
| December 31, 2023 | $143.74M | -5.3% | -5.0% |
- Relay Therapeutics, Inc. showed a decrease of -32.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Relay Therapeutics, Inc.’s cash and equivalents has grown by 100.3% (from $41.95 million to $84.02 million).
- The most recent figure is from Relay Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: